Abstract
Introduction: Informed consent involves understanding the risks and benefits of trial enrollment. This is challenging in the phase I setting since true quantitative information is never known. We therefore performed an analysis of published radiation oncology (RO) phase I trials emphasizing patient outcomes. To our knowledge, no such systemic analysis has previously been published.
American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA
Recommended Citation
Glass, C.; Den, R. B.; Dicker, A. P.; and Lawrence, Y. R.
(2010)
"Toxicity of Phase I Radiation Oncology Trials: Worldwide Experience,"
Bodine Journal: Vol. 3:
Iss.
1, Article 31.
DOI: https://doi.org/10.29046/TBJ.003.1.030
Available at:
https://jdc.jefferson.edu/bodinejournal/vol3/iss1/31
